Breast cancer is the most common cancer among women in India and the leading cause of cancer death in women in Delhi, Gurgaon and Noida. GLOBOCAN 2022 recorded around 192,020 new female breast cancer cases and 98,337 deaths in India for the year, and the ICMR National Cancer Registry Programme shows Delhi among the highest age-adjusted incidence registries in the country with a sustained rise in women aged 35 to 55. The stage at diagnosis is the single factor that determines whether a woman is offered breast conservation with a short course of radiotherapy and endocrine tablets, or neoadjuvant chemotherapy with immunotherapy followed by mastectomy and post-operative radiation. This page explains how breast cancer is staged at leading cancer centres in the region using the AJCC TNM 8th edition anatomic and prognostic systems, what each molecular subtype means for prognosis, what every stage looks like clinically, and what NCR families can expect at each step. (See the GLOBOCAN 2022 India fact sheet and NCI PDQ on breast cancer treatment.)
What Breast Cancer Staging Actually Means
Staging in breast cancer is the formal process of measuring how large the primary tumour is within the breast, how many regional lymph nodes in the axilla, internal mammary chain and supraclavicular fossa it has reached, and whether it has seeded any distant organ. The stage is built from three anatomic pieces: the size and local extent of the tumour (T), the number and location of involved regional lymph nodes (N) and the presence or absence of distant metastases (M). What makes breast cancer staging unique since 2018 is that the AJCC 8th edition integrated prognostic factors—Nottingham histological grade, oestrogen and progesterone receptor status, HER2 status, and in selected cases, a multi-gene recurrence score signature—directly into the stage group definitions rather than relegating these to separate categories. This integration means that a T3N0M0 breast cancer with ER+HER2- grade 1 histology and Oncotype Dx score below 11 qualifies as stage IIIA for anatomic staging but is reclassified as stage I for prognostic staging. (See the AJCC Cancer Staging Manual, 8th edition.)
Anatomic Versus Prognostic TNM Staging in Breast Cancer
The AJCC 8th edition breast cancer staging creates two parallel systems: anatomic TNM staging and prognostic stage groups. Anatomic TNM is the traditional size-node-metastasis system based on physical measurement of the primary tumour, the number of axillary, internal mammary and supraclavicular lymph nodes involved, and the presence or absence of distant organ metastases. Prognostic stage groups take the anatomic TNM and then layer in the Nottingham tumour grade, ER/PR/HER2 receptor status, and in intermediate-risk cases, either the 21-gene Oncotype Dx Recurrence Score, the 70-gene MammaPrint score, or Prosigna for determining prognosis independently of size and nodes. at leading cancer centres in the region in Delhi-NCR, both the anatomic and prognostic stages are reported on every breast cancer case so that clinicians understand the raw TNM and can layer in clinical judgment about the true risk of the individual patient. (See the NCI PDQ breast cancer staging, treatment and prognosis.)
The T Descriptor: From Tis to T4d in Breast Cancer
The T (tumour size and local extent) descriptor in breast cancer staging measures the longest dimension of the primary invasive carcinoma in the breast, and adds modifiers for skin and chest wall involvement. Tis is carcinoma in situ: DCIS (ductal carcinoma in situ) and LCIS (lobular carcinoma in situ) without invasion of the basement membrane. T1 is an invasive tumour 20 mm or less: T1a is 5 mm or less, T1b is 5 mm to 10 mm, T1c is 10 mm to 20 mm. T2 is 20 mm to 50 mm. T3 is larger than 50 mm. T4 describes direct extension to the chest wall or skin: T4a is skin involvement in the form of erosion, ulceration, or satellite nodules in the skin of the breast, T4b is chest wall involvement defined as invasion of the pectoralis major muscle or the ribs, T4c is both skin and chest wall involvement, and T4d is inflammatory breast cancer defined by the clinical and pathological finding of dermal lymphatic invasion with erythema and oedema (peau d’orange). (See the AJCC Cancer Staging Manual 8th edition, breast cancer chapter.)
Sentinel Lymph Node Biopsy and Axillary Staging
Lymph node staging in breast cancer has evolved dramatically with the use of sentinel lymph node biopsy (SLNB) instead of routine axillary lymph node dissection for early-stage disease. SLNB uses a combination of a blue dye, technetium-99m sulfur colloid or indocyanine green injected at the tumour or areola to identify the first lymph node (or occasionally two to three nodes) draining that breast region. A sample of the sentinel node(s) is taken intraoperatively at leading cancer centres in the region for frozen section, and the patient avoids full axillary clearance if the sentinel node is negative. Intraoperative imprint cytology or one-step nucleic acid amplification (OSNA) provide same-day assessment of sentinel node status at the major Delhi-NCR cancer centres. The Z11 trial published in JAMA in 2011 showed that axillary lymph node dissection can be omitted entirely in sentinel-node-positive patients with 1 to 2 involved nodes who are undergoing breast conservation and radiotherapy. (See the Giuliano et al, Z11 trial, JAMA 2011.)
The N Descriptor: From N0 to N3 in Breast Cancer
The N (lymph node) descriptor in breast cancer records the number and location of involved regional lymph nodes, with a critical distinction between sentinel nodes and non-sentinel nodes, and between axillary and internal mammary and supraclavicular nodes. N0 is no regional lymph node metastasis. N1 is metastasis in 1 to 3 axillary lymph nodes and/or in internal mammary nodes detected on sentinel lymph node biopsy but not on imaging. N2 is metastasis in 4 to 9 axillary lymph nodes, or in clinically detected internal mammary nodes without axillary node involvement. N3 is 10 or more axillary nodes, or infraclavicular lymph nodes, or internal mammary and axillary nodes, or supraclavicular lymph nodes. At a tertiary cancer centre, a tertiary cancer centre and all major Delhi-NCR cancer centres, a detailed pathology report on the sentinel node(s) is generated specifying exact number positive, size of metastases, and presence or absence of extranodal extension. (See the NCI PDQ on breast cancer nodal staging.)
The M Descriptor: Stage IV Breast Cancer
M0 means no clinical or radiological evidence of distant metastases. M1 means the breast cancer has spread to distant organs: bone, lung, liver, brain, adrenal glands, distant lymph nodes outside the locoregional drainage basin, the contralateral breast, and occasionally skin distant from the primary. For practical staging purposes, leading cancer centres divide M1 breast cancer into two prognostic categories introduced in AJCC 8th edition: non-visceral metastases (bone and distant lymph nodes only) and visceral metastases (lung, liver, brain parenchyma, and leptomeningeal involvement). The median overall survival for stage IV HER2-negative, ER/PR-positive breast cancer on endocrine therapy is now 5 to 7 years, while HER2-positive metastatic breast cancer on trastuzumab and pertuzumab has median overall survival approaching 10 years at specialist NCR centres. (See the NCI PDQ on stage IV breast cancer prognosis.)
Hormone Receptor Status: ER, PR and the Luminal Phenotype
Oestrogen receptor (ER) and progesterone receptor (PR) status are measured by immunohistochemistry on every primary breast cancer and every metastatic site at leading cancer centres in the region and all other major NCR breast pathology labs using standard clinical threshold of 1 percent or greater positive nuclei. ER-positive, PR-positive (luminal) breast cancer accounts for roughly 70 to 75 percent of all invasive breast cancers in Delhi-NCR registries, responds to endocrine therapy with aromatase inhibitors, tamoxifen or fulvestrant, and has superior prognosis compared to triple-negative disease. ER and PR status also stratifies response to additional endocrine agents like the cyclin-dependent kinase 4/6 inhibitors palbociclib, ribociclib and abemaciclib, which are now first-line agents for ER-positive metastatic breast cancer at leading cancer centres in the region and all major NCR cancer centres. (See the NCI PDQ on ER/PR status and hormone therapy in breast cancer.)
HER2 Status: Gene Amplification and Protein Overexpression
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase growth factor receptor, and breast cancers with HER2 gene amplification or protein overexpression (HER2-positive) account for roughly 15 to 20 percent of all invasive breast cancers and have distinct biology and treatment pathways. HER2 status is determined on every primary breast cancer and every metastatic site at leading cancer centres in the region using immunohistochemistry (IHC) scored 0, 1+, 2+ or 3+, with reflex fluorescence in situ hybridisation (FISH) on 2+ cases to determine true amplification. HER2-positive breast cancer (IHC 3+ or IHC 2+ FISH+) is treated with trastuzumab, pertuzumab, and T-DM1 (trastuzumab emtansine) in various combinations depending on stage and clinical context. (See the NCI PDQ on HER2-positive breast cancer.)
Triple-Negative Breast Cancer: Definition and Prevalence in Delhi-NCR
Triple-negative breast cancer (TNBC) is defined as ER-negative, PR-negative and HER2-negative and accounts for approximately 10 to 15 percent of all invasive breast cancers across Indian registries. TNBC is enriched for basal-like transcriptional profiles, high Nottingham grade, younger age at diagnosis, and African ancestry genetic ancestry at population level, though it is seen across all ethnic groups. TNBC has aggressive biology, higher propensity for visceral metastases and brain involvement, and worse prognosis than hormone-receptor-positive disease, particularly in the metastatic setting. leading cancer centres now routinely perform tumour mutational burden and PD-L1 assessment on TNBC for eligibility for immunotherapy, and BRCA testing for homologous recombination deficiency-driven cancers. (See the Foulkes et al, triple-negative breast cancer review, JCO 2020.)
Nottingham Histological Grade: Grade 1, 2, 3 and Prognostic Significance
Nottingham histological grade is assessed on the primary tumour of every invasive breast cancer at leading cancer centres in the region using three components: mitotic rate (10 high-power fields), nuclear pleomorphism, and tubule formation. Each component is scored 1, 2, or 3, summed to create a score of 3 to 9, and then converted to Nottingham grade: grade 1 (3-5 points), grade 2 (6-7 points), grade 3 (8-9 points). Grade 1 (well-differentiated) tumours have low mitotic rate, minimal pleomorphism and prominent tubule formation. Grade 3 (poorly differentiated) tumours have high mitotic rate, marked nuclear pleomorphism and little to no tubule formation. Grade 2 (intermediate) tumours fall between the two. Grade is now directly incorporated into the prognostic stage grouping in the AJCC 8th edition, meaning a grade 1 T1cN0M0 tumour is prognostic stage I despite anatomic stage IIA. (See the AJCC Cancer Staging Manual 8th edition.)
Oncotype DX 21-Gene Recurrence Score in Breast Cancer Prognosis
For ER-positive, HER2-negative, node-negative breast cancer, the Oncotype DX 21-gene recurrence score is used at leading cancer centres in the region to quantify the risk of distant recurrence and guide decisions about adjuvant chemotherapy. Oncotype Dx test on the primary tumour provides a recurrence score (RS) of 0 to 100 in three prognostic categories: RS 0-10 is very low risk, RS 11-25 is low risk, RS 26-100 is intermediate-to-high risk. Patients with RS less than or equal to 25 have good outcomes with endocrine therapy alone and do not routinely need chemotherapy, while those with RS greater than or equal to 26 benefit from perioperative chemotherapy. The test also provides HER2, ER, PR quantification scores. The TAILORx trial published in NEJM in 2015 showed that patients with intermediate RS (16-25) could safely omit chemotherapy if age greater than or equal to 50, while the RxPONDER trial showed that postmenopausal women with 1-3 positive nodes and RS less than or equal to 25 could also be spared chemotherapy. (See Sparano et al, TAILORx, NEJM 2015.)
MammaPrint 70-Gene Score and Prosigna 50-Gene PAM50 Signature
For ER-positive, HER2-negative breast cancer, two additional multigene signatures are available as alternatives to Oncotype DX at major Delhi-NCR cancer centres. MammaPrint is a 70-gene assay that classifies breast cancers into low-risk or high-risk groups based on gene expression patterns, and studies show its clinical utility is comparable to Oncotype DX for decision-making about adjuvant chemotherapy. Prosigna (PAM50) is a 50-gene intrinsic molecular subtype classifier that assigns tumours to luminal A, luminal B, HER2-enriched, or basal-like categories and provides a risk of recurrence score. At a tertiary cancer centre and a tertiary cancer centre, both Oncotype DX and Prosigna or MammaPrint are sometimes ordered in parallel for complex intermediate-risk cases. (See the NCI PDQ on genomic testing in breast cancer.)
Diagnosing Breast Cancer: Imaging and Biopsy Pathways in Delhi-NCR
The diagnosis of breast cancer in Delhi-NCR begins with imaging: mammography, digital breast tomosynthesis (DBT), and ultrasound are performed at leading cancer centres in the region and all major imaging centres. Any suspicious lesion on imaging (typically BI-RADS category 4 or 5 on mammography or ultrasound) is biopsied using either 14-gauge core needle biopsy under ultrasound or stereotactic guidance for microcalcifications, or excision biopsy. Core needle biopsy provides a histological diagnosis in approximately 95 percent of cases at the major NCR centres and avoids the need for open excision biopsy in most situations. Excision biopsy is reserved for lesions with high clinical suspicion where core biopsy is non-diagnostic, for complete histological characterisation of high-grade lesions, and for lesions that have features of atypia on core biopsy. (See the NCI PDQ on breast cancer diagnosis.)
Staging Workup for Newly Diagnosed Breast Cancer
Staging investigations for a newly diagnosed breast cancer vary with the size, grade and biological subtype of the primary tumour. For small (T1) ER+HER2- grade 1 tumours, mammographic follow-up of the contralateral breast and clinical examination may be sufficient to exclude distant metastases. For T2 and larger lesions, any grade 3 tumours, any HER2-positive or triple-negative tumours, or any lesions with clinical features of advanced disease, a whole-body staging workup is performed at leading cancer centres in the region. This typically includes a contrast-enhanced CT of the thorax and abdomen, or a whole-body FDG-PET-CT for higher-risk presentations. MRI of the breast is increasingly used to assess the extent of disease in the ipsilateral breast and to screen for occult disease in the contralateral breast in high-risk patients. (See the NCI PDQ on breast cancer staging investigation.)
Stage 0 Breast Cancer: DCIS and Surgical Approach
Ductal carcinoma in situ (DCIS) is diagnosed in approximately 15 to 20 percent of newly detected breast cancers in mammographically screened populations in Delhi-NCR. DCIS is non-invasive disease: cancer cells are confined to the ducts and lobules of the breast without invasion of the basement membrane. The risk of progression to invasive disease ranges from approximately 20 to 30 percent over 10 years if left untreated, which is why DCIS is considered a precursor lesion rather than stage 0 cancer in the strict sense but is classified as Tis (carcinoma in situ) in the TNM system. Surgical excision with negative margins is the standard treatment, followed by radiotherapy to reduce ipsilateral breast recurrence risk by approximately 50 percent. Endocrine therapy (tamoxifen or aromatase inhibitor) is considered for selected patients with higher-grade DCIS. The DCIS score, a multi-gene assay similar to Oncotype DX, provides prognostic information to guide decisions about radiotherapy and endocrine therapy in intermediate-risk cases. (See Wapnir et al, ECOG-ACRIN E5194 DCIS radiotherapy follow-up, JCO 2015.)
Stage IA Breast Cancer: Small Invasive Tumours and Breast Conservation
Stage IA breast cancer is defined as T1a-cN0M0 (tumours 5 mm or less with no lymph node involvement and no distant metastases) or in the prognostic system as small ER+PR+ grade 1 tumours without nodal involvement and with low Oncotype Dx scores. These are typically treated with breast-conserving surgery (lumpectomy) plus sentinel lymph node biopsy and whole-breast radiotherapy, or with mastectomy without radiotherapy for small tumours. Adjuvant chemotherapy is rarely indicated for true stage IA disease. Endocrine therapy with an aromatase inhibitor or tamoxifen for 5 to 10 years is given to ER-positive cases. Five-year survival for stage IA breast cancer approaches 98 to 100 percent at a tertiary cancer centre, a tertiary cancer centre and all major Delhi-NCR centres. (See the NCI PDQ on stage IA breast cancer prognosis and treatment.)
Stage IB Breast Cancer: Prognostic Stage Groups and Treatment
Stage IB in the AJCC 8th edition prognostic system is defined as ER+PR+HER2- grade 1 tumours with 1 to 3 positive axillary nodes, or HER2-positive or grade 3 ER+PR+ tumours regardless of nodal status and without distant metastases. Treatment for anatomic stage IB-IIA disease typically involves breast-conserving surgery or mastectomy with sentinel lymph node biopsy or axillary dissection, followed by whole-breast radiotherapy (for conservation) or chest wall and nodal radiotherapy (for mastectomy with 1-3 positive nodes). Adjuvant chemotherapy is indicated for most HER2-positive and grade 3 ER+PR+ tumours. Endocrine therapy is given to all ER+PR+ cases, and trastuzumab and pertuzumab are given to all HER2-positive cases. Five-year survival for stage IB disease is approximately 92 to 98 percent depending on the biological subtype. (See the NCI PDQ on stage IB breast cancer.)
Stage II Breast Cancer: Intermediate Risk Tumours
Stage II breast cancer includes T0-T2 tumours with 1 to 9 positive lymph nodes (N1-N2) and no distant metastases, or larger T3 tumours with no nodal involvement (N0). The prognostic stage groupings in the AJCC 8th edition further stratify stage II disease based on receptor status, grade and gene expression scores: ER+PR+ grade 1 tumours without nodal involvement may be downstaged to stage I, while ER+PR+ grade 3 or any HER2-positive tumours remain stage IIA or higher. Treatment for stage II breast cancer typically includes breast-conserving surgery or mastectomy with lymph node assessment, chemotherapy followed by radiotherapy, endocrine therapy (for ER+PR+ cases) and trastuzumab and pertuzumab (for HER2-positive cases). Five-year survival for stage II breast cancer is approximately 87 to 95 percent depending on the subtype and nodal burden. (See the NCI PDQ on stage II breast cancer.)
Stage IIIA Breast Cancer: Locally Advanced Disease
Stage IIIA breast cancer includes T0-T2 tumours with 10 or more positive axillary lymph nodes, or T3 tumours with 1 or more positive nodes, or T4 tumours with any nodal status (N0-N+), all without distant metastases. This is locally advanced disease and represents a shift in treatment paradigm: neoadjuvant systemic therapy is now given before surgery to downstage the primary and nodal disease and to assess chemosensitivity. Standard neoadjuvant regimens at leading cancer centres in the region include anthracycline-based chemotherapy (AC or EC) followed by taxanes (paclitaxel or docetaxel), and for HER2-positive disease, trastuzumab and pertuzumab are added during neoadjuvant therapy. After completion of neoadjuvant therapy, response is assessed by imaging and physical examination, and surgery is planned based on imaging and clinical response. Postoperative radiotherapy to the chest wall and regional lymph nodes is standard. Five-year survival for stage IIIA breast cancer is approximately 72 to 90 percent. (See the NCI PDQ on stage IIIA breast cancer.)
Stage IIIB Breast Cancer: T4 and Inflammatory Breast Cancer
Stage IIIB breast cancer is primarily T4 disease (invasion of the chest wall or skin, or inflammatory breast cancer [T4d]). Inflammatory breast cancer is a particularly aggressive subtype accounting for 1 to 5 percent of all breast cancer diagnoses, presenting with erythema, oedema and peau d’orange of the breast due to dermal lymphatic invasion and tumour emboli, and is by definition stage IIIB or IV. The standard of care for stage IIIB disease including inflammatory breast cancer is neoadjuvant systemic therapy using the same anthracycline and taxane-based regimens used for stage IIIA, with trastuzumab and pertuzumab for HER2-positive cases. Response assessment after neoadjuvant therapy guides the feasibility of mastectomy with chest wall resection if needed. Postoperative radiotherapy to the chest wall, all nodal stations and even the contralateral internal mammary nodes is performed. The prognosis of stage IIIB disease is significantly worse than stage IIIA, with five-year survival in the 30 to 60 percent range, and inflammatory breast cancer has five-year survival of approximately 40 percent even with multimodal therapy. (See the NCI PDQ on inflammatory breast cancer.)
Stage IV Breast Cancer: Metastatic Disease
Stage IV breast cancer is any tumour of any size with distant metastases (M1) regardless of nodal status. Metastatic breast cancer is incurable but highly treatable, particularly for ER+PR+ and HER2-positive subtypes. The treatment of stage IV disease depends on receptor status, sites of metastases (visceral versus non-visceral), and performance status. ER+PR+ metastatic breast cancer is managed with first-line endocrine therapy (usually an aromatase inhibitor or fulvestrant) plus a cyclin-dependent kinase 4/6 inhibitor (palbociclib, ribociclib, abemaciclib) at leading cancer centres in the region, with typical progression-free survival of 22 to 28 months before resistance develops. HER2-positive metastatic breast cancer is managed with dual HER2 blockade using trastuzumab and pertuzumab plus chemotherapy, or with T-DM1 (trastuzumab emtansine) and pertuzumab, or with newer agents like tucatinib and trastuzumab deruxtecan. Triple-negative metastatic breast cancer is treated with chemotherapy or immunotherapy depending on PD-L1 status and tumour mutational burden. Median overall survival for metastatic ER+PR+ disease is now 5 to 7 years, HER2-positive metastatic disease is approaching 10 years, while TNBC remains approximately 12 to 15 months. (See the NCI PDQ on stage IV breast cancer treatment and prognosis.)
Cost of Breast Cancer Care Across Delhi, Gurgaon and Noida
The cost of treating breast cancer in the Delhi-NCR region varies by hospital and treatment intensity. Diagnostic mammography and ultrasound range from INR 1,500 to 5,000 at a tertiary cancer centre or government units to INR 3,000 to 8,000 at major private hospitals. Core needle biopsy ranges from INR 3,000 to 10,000. A complete staging workup including mammography, ultrasound, MRI, and PET-CT ranges from INR 60,000 to 2,00,000 depending on modalities used and hospital tier. Breast-conserving surgery ranges from INR 1,50,000 to 4,50,000 depending on hospital; modified radical mastectomy ranges from INR 2,00,000 to 5,50,000. Chemotherapy costs depend on regimen but for four cycles of anthracycline-based chemotherapy plus four cycles of taxane chemotherapy range from approximately INR 3,00,000 to 8,00,000. Radiotherapy for 25 to 28 fractions ranges from INR 50,000 to 2,00,000 depending on technique. Trastuzumab and pertuzumab for HER2-positive disease range from INR 1,00,000 to 5,00,000 per year depending on access to biosimilars. Endocrine therapy for ER+PR+ disease with aromatase inhibitors or tamoxifen is relatively inexpensive at INR 500 to 3,000 per month. Many private hospitals offer cancer care packages that bundle surgery, chemotherapy and radiotherapy at discounted rates. The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) covers breast cancer treatment packages at empanelled NCR hospitals for eligible families. (See the PMJAY hospital empanelment portal.)
Breast Cancer FAQs for NCR Patients and Families
Is a lump always cancer? No. Most breast lumps are benign fibroadenomas, cysts, or fat necrosis. Any new lump or area of concern should be evaluated with imaging (mammography or ultrasound) followed by biopsy if needed, but the majority of biopsies are benign. Is breast cancer hereditary? Approximately 5 to 10 percent of breast cancers are hereditary due to germline mutations in BRCA1, BRCA2, PTEN, TP53, CHEK2, PALB2 and other genes. If you have a strong family history of breast cancer, ovarian cancer, or pancreatic cancer, genetic testing should be offered. Do I need chemotherapy? Not always. ER+PR+ grade 1 T1 tumours with low Oncotype DX scores do not require chemotherapy and are managed with endocrine therapy alone. Chemotherapy is indicated for grade 3, HER2-positive, triple-negative, or node-positive tumours. Will I lose my hair? Chemotherapy regimens containing anthracyclines and taxanes cause hair loss in the majority of patients. Scalp cooling devices reduce hair loss in some patients and are available at leading cancer centres in the region. Can I still have children after breast cancer treatment? Yes. For pre-menopausal women who are not pregnant at the time of diagnosis, chemotherapy, radiation and hormonal therapy can temporarily affect fertility, but many women retain ovarian function after breast cancer treatment and are able to conceive naturally or with assisted reproductive technology. Genetic counselling is important for BRCA carriers. What is my life expectancy? Prognosis depends on stage, grade, receptor status and your overall health, but five-year survival for all stages combined now exceeds 90 percent in developed settings. Stage I-II disease has five-year survival greater than 95 percent, stage III 70 to 90 percent, and stage IV approximately 28 percent (though this is rapidly improving with new therapies). (See the NCI PDQ on breast cancer prognosis.)
Overview
Treatment Options